‘Mind-boggling’ IO Data, Plus New Combos, Targets for NSCLC
Drs West, Aggarwal, and Patel discuss the ‘mind-boggling,’ ‘humbling,’ and ‘amazing’ advances in survival statistics and targeted therapies for NSCLC presented at ASCO 2019.
Related Articles
VOD Foro de Pacientes de Terapias Dirigidas en Cáncer de Pulmón 2024 en Español | CancerGRACE
¡El vĂdeo completo bajo demanda está disponible para verlo!
VOD Foro de Pacientes de Terapias Dirigidas en Cáncer de Pulmón 2024 en Español
Este evento educativo para pacientes, en directo, virtual e interactivo, incluye presentaciones y mesas redondas que cubren temas generales relevantes para u…
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology
8506 Background: First line therapy options for advanced NSCLC without actionable molecular alterations include immunotherapy (IO) -/+ chemotherapy or chemotherapy alone. NRG-LU002 was a randomized…
Association of Immunotherapy Duration With Overall Survival in Advanced Non–Small Cell Lung Cancer
This cohort study of advanced non–small cell lung cancer patients assesses practice patterns surrounding immunotherapy discontinuation at 2 years and evaluates the association of duration…
Lauzon
Media Inquires: email: Press@FansMeetIdols.com phone: (404) 999-5149Fans Meet Idols LLC – Copyright 2024PrivacyTerms
Lauzon
Media Inquires: email: Press@FansMeetIdols.com phone: (404) 999-5149Fans Meet Idols LLC – Copyright 2024PrivacyTerms
How Scientific Publishers’ Extreme Fees Put Profit Over Progress
On April 17, the premier journal NeuroImage’s entire editorial team, comprising more than 40 scientists, resigned over the “unethical fees” charged by the journal’s academic…
How Scientific Publishers’ Extreme Fees Put Profit Over Progress
On April 17, the premier journal NeuroImage’s entire editorial team, comprising more than 40 scientists, resigned over the “unethical fees” charged by the journal’s academic…
Advertisers Flee X as Outcry Grows Over Musk’s Endorsement of Antisemitic Post
Disney, Apple and Lionsgate halted marketing on X, formerly Twitter, as Elon Musk faced a furor over antisemitic abuse on his social media platform.
Association of Immunotherapy Duration With Overall Survival in Advanced Non–Small Cell Lung Cancer
This cohort study of advanced non–small cell lung cancer patients assesses practice patterns surrounding immunotherapy discontinuation at 2 years and evaluates the association of duration…